Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an update.
Race Oncology Ltd. announced a change in the director’s interest, specifically involving Daniel Tillett. The change includes the acquisition of 470,545 fully paid ordinary shares and 432,680 options exercisable at $1.67, expiring on June 30, 2029. Additionally, 2,000,000 options exercisable at $2.65, expiring on November 29, 2025, were disposed of. This adjustment in securities was executed through a cashless exercise and was approved at the company’s Annual General Meeting on November 24, 2025. The impact of these changes reflects a strategic shift in the director’s investment, potentially influencing the company’s market positioning and stakeholder interests.
More about Race Oncology Ltd.
Race Oncology Ltd. operates in the biotechnology industry, focusing on the development and commercialization of cancer therapies. The company is known for its innovative approaches to cancer treatment, aiming to provide effective solutions for patients and healthcare providers.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.